Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting
IMUNON (NASDAQ: IMNN) announced that an abstract detailing a Phase 2 study involving IMNN-001 combined with bevacizumab (Avastin) and neoadjuvant chemotherapy for advanced epithelial ovarian cancer patients has been accepted for presentation at the American Society of Clinical Oncology (ASCO) annual meeting. The presentation will occur on June 3, 2024, during the Gynecologic Cancer session at the event in Chicago, which runs from May 31 to June 4.
Lead investigator Dr. Amir A Jazaeri from The University of Texas MD Anderson Cancer Center will present the study, which aims to evaluate the effect of this combination therapy in newly diagnosed patients. The study is actively recruiting participants in the U.S. and is substantially funded by Break Through Cancer.
According to Dr. Sebastien Hazard, IMUNON’s Chief Medical Officer, the synergy observed between IMNN-001 and bevacizumab in pre-clinical experiments is promising, and the company aims to complete enrollment quickly to address this critical clinical question.
- Abstract accepted for presentation at a prestigious ASCO annual meeting.
- Focus on advanced epithelial ovarian cancer treatment with a combination of IMNN-001 and bevacizumab.
- Backed by substantial funding from Break Through Cancer.
- Lead investigator from the renowned MD Anderson Cancer Center.
- Promising pre-clinical synergy between IMNN-001 and bevacizumab.
- Study is still in the recruitment phase, indicating it's not near completion.
- Uncertainty regarding clinical outcomes until the study concludes.
- Potential delays in patient enrollment could impact timelines.
LAWRENCEVILLE, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that an abstract describing a Phase 2 study with IMNN-001 plus bevacizumab (Avastin®) and neoadjuvant chemotherapy in advanced epithelial ovarian cancer patients has been accepted for presentation at the American Society of Clinical Oncology (ASCO) annual meeting, to be held in Chicago from May 31st to June 4th.
The abstract, titled “A phase II study evaluating the effect of IMNN-001 on second-look laparoscopy when administered in combination with bevacizumab and neoadjuvant chemotherapy in patients newly diagnosed with advanced epithelial ovarian cancer,” will be presented on June 3rd at the Gynecologic Cancer session between 9:00 a.m. and 12:00 p.m. CT by lead investigator Amir A Jazaeri, M.D., Professor of Gynecological Oncology & Reproductive Medicine at The University of Texas MD Anderson Cancer Center. The study is actively recruiting patients in the U.S.
Abstract #: TPS5633
Poster Board #: 498a
Session Title: Gynecologic Cancer
Location: Hall A
“This study, substantially funded by Break Through Cancer, and with MD Anderson as the leading clinical site, is a pivotal part of IMUNON’s IL-12 gene therapy development for women with ovarian cancer. The combination with bevacizumab makes a lot of sense as we have observed synergies in pre-clinical experiments. We hope to complete enrollment of this study quickly to answer this important clinical question,” said Dr. Sebastien Hazard, IMUNON’ chief medical officer.
About IMUNON
IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the coding of proteins and cytokines in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the coding of viral antigens that can elicit a strong immunological response. This technology may represent a promising platform for the development of vaccines in infectious diseases.
The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company is entering a first-in-human study of its COVID-19 booster vaccine (IMNN-101). We will continue to leverage these modalities and to advance the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information on IMUNON, visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure of conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible acquisitions or licenses of other technologies, assets or businesses; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.
Contacts:
| IMUNON | LHA Investor Relations |
| Jeffrey W. Church | Kim Sutton Golodetz |
| Executive Vice President, CFO | 212-838-3777 |
| and Corporate Secretary | Kgolodetz@lhai.com |
| 609-482-2455 | |
| jchurch@imunon.com |
# # #
FAQ
What is IMUNON's IMNN-001?
When will IMUNON present their Phase 2 study findings?
What is the focus of IMUNON's Phase 2 study?
Who is the lead investigator for IMUNON's Phase 2 study?
What are the key dates for the ASCO annual meeting?
What is the significance of combining IMNN-001 with bevacizumab?
Who is funding IMUNON's Phase 2 study?
